Report #2835007

Received Apr 9, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: NY
Recovered: Unknown
Vaccinated: Feb 13, 2025
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	943191	IM / LA

Symptoms (2)

Interchange of vaccine productsNo adverse event

Symptom narrative

Received Heplisav-B As First Dose, and Second Dose was Engerix-B; Initial report received on 19-Mar-2025. A nurse reported that a 21-year-old male (race, ethnicity not reported) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization as the first dose and ENGERIX-B as the second dose. No medical history or concomitant medications were reported. On 13-Feb-2025, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot # 943191, expiration date 21-Feb-2026, NDC # not reported)] intramuscularly in left deltoid. On an unknown date, the patient received ENGERIX-B (no details provided) as the second dose. There were no other side effects. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.